Director, Regulatory Writing (Temporary) at Vir Biotechnology

San Francisco, California, United States

Vir Biotechnology Logo
Not SpecifiedCompensation
Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalIndustries

Requirements

Candidates should possess a Bachelor's degree in a science or medical-related field with at least 15 years of industry experience, a Master's degree with 13 years of experience, or a PhD with 10 years of experience. Experience with common regulatory documents such as CSRs, IBs, DSURs, protocols, and clinical modules is required, along with an expert understanding of eCTD structure, the clinical development process, and document-related ICH guidelines and GxPs. Involvement with marketing applications (INDs, BLAs, NDAs, MAAs, or equivalents) is preferred, and at least 8 years of experience as a writer in biotechnology or an equivalent field is necessary. Applicants must be authorized to work in the U.S. without sponsorship.

Responsibilities

The Director, Regulatory Writing will craft clear, accurate, and compliant documents for global health authority submissions, including protocols, Investigator Brochures, Clinical Study Reports, briefing packages, and regulatory submission dossiers. They will ensure all documentation adheres to relevant regulatory guidelines and standards, such as ICH E3 and ICH M4. Responsibilities include analyzing complex scientific and medical information, translating it into understandable language, and collaborating with cross-functional teams to gather data and ensure comprehensive documentation. The role also involves managing writing projects from planning to submission, including establishing timelines and tracking progress.

Skills

Regulatory Writing
Clinical Trial Protocols
Investigator Brochures
Clinical Study Reports
Briefing Packages
NDA
IND
MAA
ICH E3
ICH M4
Scientific Writing
Medical Writing

Vir Biotechnology

Develops monoclonal antibodies for infectious diseases

About Vir Biotechnology

Vir Biotechnology develops treatments that leverage the immune system to combat infectious diseases. The company uses a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which aids in developing effective medicines. Their pipeline includes candidates for hepatitis B, hepatitis delta, HIV, and various viruses like influenza and COVID-19. Vir stands out by collaborating with industry leaders and organizations to accelerate scientific advancements, with the goal of transforming lives through innovative therapies.

San Francisco, CaliforniaHeadquarters
2016Year Founded
$640.6MTotal Funding
IPOCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement

Risks

Leadership instability due to key executive resignations may disrupt operations.
Job cuts and facility closures indicate potential financial strain.
Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

Differentiation

Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
The company focuses on immune system manipulation for targeted therapies.
Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Upsides

Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

Land your dream remote job 3x faster with AI